From: Evaluation of the efficacy of sarolaner (Simparica®) in the prevention of babesiosis in dogs
Days post-infection | Treatment group | Geometric (Arithmetic) mean | Range | Percent reduction^{a} | P-value |
---|---|---|---|---|---|
1 | 1 (Placebo) | 32.8 (33.1) | 27–39 | na | |
2 (Sarolaner 28 days earlier) | 2.3 (4.0) | 0–13 | 93.0 (87.9) | ≤ 0.0001 | |
3 (Sarolaner 21 days earlier) | 1.8 (2.1) | 0–5 | 94.6 (93.6) | ≤ 0.0001 | |
2 | 1 (Placebo) | 30.5 (30.9) | 23–38 | na | |
2 (Sarolaner 28 days earlier) | 0 | 0–0 | 100 | ≤ 0.0001 | |
3 (Sarolaner 21 days earlier) | 0 | 0–0 | 100 | ≤ 0.0001 | |
5 | 1 (Placebo) | 30.5 (30.9) | 26–38 | na | |
2 (Sarolaner 28 days earlier) | 0 | 0–0 | 100 | ≤ 0.0001 | |
3 (Sarolaner 21 days earlier) | 0 | 0–0 | 100 | ≤ 0.0001 |